ZA200100454B - A method of administering liposomal encapsulated taxane. - Google Patents
A method of administering liposomal encapsulated taxane. Download PDFInfo
- Publication number
- ZA200100454B ZA200100454B ZA200100454A ZA200100454A ZA200100454B ZA 200100454 B ZA200100454 B ZA 200100454B ZA 200100454 A ZA200100454 A ZA 200100454A ZA 200100454 A ZA200100454 A ZA 200100454A ZA 200100454 B ZA200100454 B ZA 200100454B
- Authority
- ZA
- South Africa
- Prior art keywords
- paclitaxel
- patient
- administering
- patients
- substance
- Prior art date
Links
- 238000000034 method Methods 0.000 title claims description 50
- 229940123237 Taxane Drugs 0.000 title description 41
- DKPFODGZWDEEBT-QFIAKTPHSA-N taxane Chemical class C([C@]1(C)CCC[C@@H](C)[C@H]1C1)C[C@H]2[C@H](C)CC[C@@H]1C2(C)C DKPFODGZWDEEBT-QFIAKTPHSA-N 0.000 title description 36
- RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 claims description 81
- 229930012538 Paclitaxel Natural products 0.000 claims description 80
- 229960001592 paclitaxel Drugs 0.000 claims description 80
- 239000000203 mixture Substances 0.000 claims description 57
- 238000011282 treatment Methods 0.000 claims description 36
- 238000009472 formulation Methods 0.000 claims description 27
- 239000003814 drug Substances 0.000 claims description 24
- 201000004384 Alopecia Diseases 0.000 claims description 23
- 208000033808 peripheral neuropathy Diseases 0.000 claims description 23
- 231100000360 alopecia Toxicity 0.000 claims description 21
- 201000001119 neuropathy Diseases 0.000 claims description 17
- 230000007823 neuropathy Effects 0.000 claims description 17
- ZGSPNIOCEDOHGS-UHFFFAOYSA-L disodium [3-[2,3-di(octadeca-9,12-dienoyloxy)propoxy-oxidophosphoryl]oxy-2-hydroxypropyl] 2,3-di(octadeca-9,12-dienoyloxy)propyl phosphate Chemical compound [Na+].[Na+].CCCCCC=CCC=CCCCCCCCC(=O)OCC(OC(=O)CCCCCCCC=CCC=CCCCCC)COP([O-])(=O)OCC(O)COP([O-])(=O)OCC(OC(=O)CCCCCCCC=CCC=CCCCCC)COC(=O)CCCCCCCC=CCC=CCCCCC ZGSPNIOCEDOHGS-UHFFFAOYSA-L 0.000 claims description 14
- 239000000463 material Substances 0.000 claims description 3
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 3
- 239000000126 substance Substances 0.000 claims 19
- 238000004519 manufacturing process Methods 0.000 claims 5
- 239000002502 liposome Substances 0.000 description 19
- 231100000419 toxicity Toxicity 0.000 description 16
- 230000001988 toxicity Effects 0.000 description 16
- 206010028980 Neoplasm Diseases 0.000 description 14
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 14
- 238000001802 infusion Methods 0.000 description 14
- 239000000243 solution Substances 0.000 description 14
- 229940079593 drug Drugs 0.000 description 13
- 201000011510 cancer Diseases 0.000 description 12
- 206010067484 Adverse reaction Diseases 0.000 description 10
- 230000006838 adverse reaction Effects 0.000 description 10
- 239000002904 solvent Substances 0.000 description 9
- RCINICONZNJXQF-XAZOAEDWSA-N taxol® Chemical compound O([C@@H]1[C@@]2(CC(C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3(C21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-XAZOAEDWSA-N 0.000 description 8
- 238000002512 chemotherapy Methods 0.000 description 7
- 235000012000 cholesterol Nutrition 0.000 description 7
- 150000002632 lipids Chemical class 0.000 description 7
- 208000002154 non-small cell lung carcinoma Diseases 0.000 description 7
- 241000282412 Homo Species 0.000 description 6
- 231100000371 dose-limiting toxicity Toxicity 0.000 description 6
- 238000002360 preparation method Methods 0.000 description 6
- 206010006187 Breast cancer Diseases 0.000 description 5
- 208000026310 Breast neoplasm Diseases 0.000 description 5
- 206010028116 Mucosal inflammation Diseases 0.000 description 5
- 201000010927 Mucositis Diseases 0.000 description 5
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 5
- 150000001875 compounds Chemical class 0.000 description 5
- 201000010099 disease Diseases 0.000 description 5
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 5
- 231100000226 haematotoxicity Toxicity 0.000 description 5
- 239000008194 pharmaceutical composition Substances 0.000 description 5
- WTJKGGKOPKCXLL-RRHRGVEJSA-N phosphatidylcholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCC=CCCCCCCCC WTJKGGKOPKCXLL-RRHRGVEJSA-N 0.000 description 5
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 4
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 4
- LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 description 4
- 230000000118 anti-neoplastic effect Effects 0.000 description 4
- 239000000739 antihistaminic agent Substances 0.000 description 4
- 230000008901 benefit Effects 0.000 description 4
- 210000004027 cell Anatomy 0.000 description 4
- DDRJAANPRJIHGJ-UHFFFAOYSA-N creatinine Chemical compound CN1CC(=O)NC1=N DDRJAANPRJIHGJ-UHFFFAOYSA-N 0.000 description 4
- 230000002489 hematologic effect Effects 0.000 description 4
- 230000009467 reduction Effects 0.000 description 4
- 238000002560 therapeutic procedure Methods 0.000 description 4
- 231100000331 toxic Toxicity 0.000 description 4
- 230000002588 toxic effect Effects 0.000 description 4
- 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 description 4
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- 102000029749 Microtubule Human genes 0.000 description 3
- 108091022875 Microtubule Proteins 0.000 description 3
- 206010061535 Ovarian neoplasm Diseases 0.000 description 3
- 208000003455 anaphylaxis Diseases 0.000 description 3
- 229940125715 antihistaminic agent Drugs 0.000 description 3
- 239000002246 antineoplastic agent Substances 0.000 description 3
- 239000003246 corticosteroid Substances 0.000 description 3
- 229960001334 corticosteroids Drugs 0.000 description 3
- 238000012377 drug delivery Methods 0.000 description 3
- 238000011010 flushing procedure Methods 0.000 description 3
- 230000001965 increasing effect Effects 0.000 description 3
- 230000001939 inductive effect Effects 0.000 description 3
- 210000000265 leukocyte Anatomy 0.000 description 3
- 210000004688 microtubule Anatomy 0.000 description 3
- 230000036457 multidrug resistance Effects 0.000 description 3
- 208000004235 neutropenia Diseases 0.000 description 3
- 230000036470 plasma concentration Effects 0.000 description 3
- 239000008389 polyethoxylated castor oil Substances 0.000 description 3
- 230000004044 response Effects 0.000 description 3
- 239000011780 sodium chloride Substances 0.000 description 3
- GVJHHUAWPYXKBD-IEOSBIPESA-N α-tocopherol Chemical compound OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-IEOSBIPESA-N 0.000 description 3
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 2
- 208000006820 Arthralgia Diseases 0.000 description 2
- 208000008035 Back Pain Diseases 0.000 description 2
- BPYKTIZUTYGOLE-IFADSCNNSA-N Bilirubin Chemical compound N1C(=O)C(C)=C(C=C)\C1=C\C1=C(C)C(CCC(O)=O)=C(CC2=C(C(C)=C(\C=C/3C(=C(C=C)C(=O)N\3)C)N2)CCC(O)=O)N1 BPYKTIZUTYGOLE-IFADSCNNSA-N 0.000 description 2
- 208000009079 Bronchial Spasm Diseases 0.000 description 2
- 208000014181 Bronchial disease Diseases 0.000 description 2
- 206010006482 Bronchospasm Diseases 0.000 description 2
- 206010012735 Diarrhoea Diseases 0.000 description 2
- 208000030453 Drug-Related Side Effects and Adverse reaction Diseases 0.000 description 2
- 208000002633 Febrile Neutropenia Diseases 0.000 description 2
- 206010020751 Hypersensitivity Diseases 0.000 description 2
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 2
- 208000000112 Myalgia Diseases 0.000 description 2
- 206010033128 Ovarian cancer Diseases 0.000 description 2
- 206010040047 Sepsis Diseases 0.000 description 2
- 206010041067 Small cell lung cancer Diseases 0.000 description 2
- DKGAVHZHDRPRBM-UHFFFAOYSA-N Tert-Butanol Chemical compound CC(C)(C)O DKGAVHZHDRPRBM-UHFFFAOYSA-N 0.000 description 2
- 208000007502 anemia Diseases 0.000 description 2
- 239000005557 antagonist Substances 0.000 description 2
- 239000012298 atmosphere Substances 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 238000004820 blood count Methods 0.000 description 2
- 230000037396 body weight Effects 0.000 description 2
- 229940109239 creatinine Drugs 0.000 description 2
- 229940127089 cytotoxic agent Drugs 0.000 description 2
- ZZVUWRFHKOJYTH-UHFFFAOYSA-N diphenhydramine Chemical compound C=1C=CC=CC=1C(OCCN(C)C)C1=CC=CC=C1 ZZVUWRFHKOJYTH-UHFFFAOYSA-N 0.000 description 2
- 229960000520 diphenhydramine Drugs 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 238000005538 encapsulation Methods 0.000 description 2
- 238000004108 freeze drying Methods 0.000 description 2
- 208000024963 hair loss Diseases 0.000 description 2
- 230000003676 hair loss Effects 0.000 description 2
- JYGXADMDTFJGBT-VWUMJDOOSA-N hydrocortisone Chemical compound O=C1CC[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 JYGXADMDTFJGBT-VWUMJDOOSA-N 0.000 description 2
- 208000015181 infectious disease Diseases 0.000 description 2
- 201000002364 leukopenia Diseases 0.000 description 2
- 231100001022 leukopenia Toxicity 0.000 description 2
- 201000005202 lung cancer Diseases 0.000 description 2
- 208000020816 lung neoplasm Diseases 0.000 description 2
- 231100000682 maximum tolerated dose Toxicity 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 2
- 239000002547 new drug Substances 0.000 description 2
- 230000002611 ovarian Effects 0.000 description 2
- 238000009101 premedication Methods 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 230000002035 prolonged effect Effects 0.000 description 2
- 238000001959 radiotherapy Methods 0.000 description 2
- 210000002966 serum Anatomy 0.000 description 2
- 230000006641 stabilisation Effects 0.000 description 2
- 238000011105 stabilization Methods 0.000 description 2
- 150000003431 steroids Chemical class 0.000 description 2
- -1 such as an N Substances 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 206010043554 thrombocytopenia Diseases 0.000 description 2
- 239000002691 unilamellar liposome Substances 0.000 description 2
- TZCPCKNHXULUIY-RGULYWFUSA-N 1,2-distearoyl-sn-glycero-3-phosphoserine Chemical compound CCCCCCCCCCCCCCCCCC(=O)OC[C@H](COP(O)(=O)OC[C@H](N)C(O)=O)OC(=O)CCCCCCCCCCCCCCCCC TZCPCKNHXULUIY-RGULYWFUSA-N 0.000 description 1
- TYLVGQKNNUHXIP-MHHARFCSSA-N 10-deacetyltaxol Chemical compound O([C@H]1[C@H]2[C@@](C([C@H](O)C3=C(C)[C@@H](OC(=O)[C@H](O)[C@@H](NC(=O)C=4C=CC=CC=4)C=4C=CC=CC=4)C[C@]1(O)C3(C)C)=O)(C)[C@@H](O)C[C@H]1OC[C@]12OC(=O)C)C(=O)C1=CC=CC=C1 TYLVGQKNNUHXIP-MHHARFCSSA-N 0.000 description 1
- 206010002198 Anaphylactic reaction Diseases 0.000 description 1
- 206010063119 Anaphylactoid shock Diseases 0.000 description 1
- 208000019901 Anxiety disease Diseases 0.000 description 1
- 206010048610 Cardiotoxicity Diseases 0.000 description 1
- 206010009944 Colon cancer Diseases 0.000 description 1
- ZWZWYGMENQVNFU-UHFFFAOYSA-N Glycerophosphorylserin Natural products OC(=O)C(N)COP(O)(=O)OCC(O)CO ZWZWYGMENQVNFU-UHFFFAOYSA-N 0.000 description 1
- 102000001554 Hemoglobins Human genes 0.000 description 1
- 108010054147 Hemoglobins Proteins 0.000 description 1
- 239000000232 Lipid Bilayer Substances 0.000 description 1
- 206010025323 Lymphomas Diseases 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 208000007650 Meningeal Carcinomatosis Diseases 0.000 description 1
- ZDZOTLJHXYCWBA-VCVYQWHSSA-N N-debenzoyl-N-(tert-butoxycarbonyl)-10-deacetyltaxol Chemical compound O([C@H]1[C@H]2[C@@](C([C@H](O)C3=C(C)[C@@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)C=4C=CC=CC=4)C[C@]1(O)C3(C)C)=O)(C)[C@@H](O)C[C@H]1OC[C@]12OC(=O)C)C(=O)C1=CC=CC=C1 ZDZOTLJHXYCWBA-VCVYQWHSSA-N 0.000 description 1
- 208000001894 Nasopharyngeal Neoplasms Diseases 0.000 description 1
- 206010061306 Nasopharyngeal cancer Diseases 0.000 description 1
- 206010028813 Nausea Diseases 0.000 description 1
- 206010028817 Nausea and vomiting symptoms Diseases 0.000 description 1
- REYJJPSVUYRZGE-UHFFFAOYSA-N Octadecylamine Chemical compound CCCCCCCCCCCCCCCCCCN REYJJPSVUYRZGE-UHFFFAOYSA-N 0.000 description 1
- 229920002685 Polyoxyl 35CastorOil Polymers 0.000 description 1
- 206010037660 Pyrexia Diseases 0.000 description 1
- 206010041549 Spinal cord compression Diseases 0.000 description 1
- GUGOEEXESWIERI-UHFFFAOYSA-N Terfenadine Chemical compound C1=CC(C(C)(C)C)=CC=C1C(O)CCCN1CCC(C(O)(C=2C=CC=CC=2)C=2C=CC=CC=2)CC1 GUGOEEXESWIERI-UHFFFAOYSA-N 0.000 description 1
- 206010070863 Toxicity to various agents Diseases 0.000 description 1
- 102000004243 Tubulin Human genes 0.000 description 1
- 108090000704 Tubulin Proteins 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 238000007792 addition Methods 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 230000036783 anaphylactic response Effects 0.000 description 1
- 125000000129 anionic group Chemical group 0.000 description 1
- 229940045799 anthracyclines and related substance Drugs 0.000 description 1
- 230000001093 anti-cancer Effects 0.000 description 1
- 230000001387 anti-histamine Effects 0.000 description 1
- 230000000259 anti-tumor effect Effects 0.000 description 1
- 239000000043 antiallergic agent Substances 0.000 description 1
- 229940034982 antineoplastic agent Drugs 0.000 description 1
- 230000036506 anxiety Effects 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000000740 bleeding effect Effects 0.000 description 1
- 210000000481 breast Anatomy 0.000 description 1
- 231100000259 cardiotoxicity Toxicity 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 125000002091 cationic group Chemical group 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 208000029742 colonic neoplasm Diseases 0.000 description 1
- 231100000026 common toxicity Toxicity 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 238000011443 conventional therapy Methods 0.000 description 1
- 230000001186 cumulative effect Effects 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 231100000673 dose–response relationship Toxicity 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 239000000706 filtrate Substances 0.000 description 1
- 229930182470 glycoside Natural products 0.000 description 1
- 150000002338 glycosides Chemical class 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 229960000890 hydrocortisone Drugs 0.000 description 1
- 230000009610 hypersensitivity Effects 0.000 description 1
- 230000005847 immunogenicity Effects 0.000 description 1
- 239000011261 inert gas Substances 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 239000008206 lipophilic material Substances 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 230000036210 malignancy Effects 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 230000010534 mechanism of action Effects 0.000 description 1
- 230000001394 metastastic effect Effects 0.000 description 1
- 206010061289 metastatic neoplasm Diseases 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 230000008693 nausea Effects 0.000 description 1
- 231100000228 neurotoxicity Toxicity 0.000 description 1
- 230000007135 neurotoxicity Effects 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 210000000440 neutrophil Anatomy 0.000 description 1
- 239000012454 non-polar solvent Substances 0.000 description 1
- 230000008520 organization Effects 0.000 description 1
- QUANRIQJNFHVEU-UHFFFAOYSA-N oxirane;propane-1,2,3-triol Chemical compound C1CO1.OCC(O)CO QUANRIQJNFHVEU-UHFFFAOYSA-N 0.000 description 1
- 150000003904 phospholipids Chemical class 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 238000002203 pretreatment Methods 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 230000005855 radiation Effects 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 230000000306 recurrent effect Effects 0.000 description 1
- 208000000587 small cell lung carcinoma Diseases 0.000 description 1
- 239000011877 solvent mixture Substances 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 230000002459 sustained effect Effects 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 239000012747 synergistic agent Substances 0.000 description 1
- 238000007910 systemic administration Methods 0.000 description 1
- 231100000057 systemic toxicity Toxicity 0.000 description 1
- 229940063683 taxotere Drugs 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- SDCJNZZAOLRVCP-GTOSQJSUSA-N tetramyristoyl cardiolipin Chemical compound CCCCCCCCCCCCCC(=O)OC[C@@H](OC(=O)CCCCCCCCCCCCC)COP(O)(=O)OCC(O)COP(O)(=O)OC[C@H](OC(=O)CCCCCCCCCCCCC)COC(=O)CCCCCCCCCCCCC SDCJNZZAOLRVCP-GTOSQJSUSA-N 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 238000011287 therapeutic dose Methods 0.000 description 1
- 229960001295 tocopherol Drugs 0.000 description 1
- 239000011732 tocopherol Substances 0.000 description 1
- 238000011269 treatment regimen Methods 0.000 description 1
- 239000003981 vehicle Substances 0.000 description 1
- 238000003260 vortexing Methods 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Description
.
A METHOD OF ADMINISTERING LIPOSOMAL ENCAPSULATED
TAXANE :
= The present invention relates to a method for reducing the incidence of adverse reactions in human patients undergoing paclitaxel treatment.
The use of taxanes, such as paclitaxel, as anti-tumor agents for patients suffering from diseases such as ovarian and breast cancer, is known. In addition, paclitaxel has been shown to be clinically potent as a synergistic agent when used in conjunction with other chemotherapy and radiation treatment. Paclitaxel has a unique mechanism of action and a broad spectrum of anticancer activity because paclitaxel shows stabilization of microtubules rather than disassembly of microtubules.
However, paclitaxel has extremely low solubility in water, which makes it difficult to provide a suitable dosage form. Currently, paclitaxel is prepared and administered in a vehicle containing Cremophor EL (a polyethoxylated castor oil) and ethanol in a 50:50 (vol/vol) ratio. This solution is diluted 1:10 in saline before being administered to humans. The stability of paclitaxel once diluted in saline solution is quite low. The drug degrades within 24 hours and, thus, handling of dosage for the patients becomes very difficult. Since, the drug precipitates from dilution. an on-line filter is utilized for the infusion of the drug to the patients.
As with most chemotherapeutic agents, conventional paclitaxel therapy is accompanied by a variety of undesirable side effects that cause discomfort and that can be life threatening. For example, alopecia (hair loss) occurs in 87% of all patients studied and nausea/vomiting occurs in 52% of patients. See Physicians
Desk Reference, 54" Ed. Taxol® treatment is also frequently accompanied by neuropathy. The Physicians Desk Reference, 54th edition, indicates that 60% of treated paticnts experience peripheral neuropathy. In addition, 60% of treated patients cxperience myalgia and/or arthralgia. Among other listed toxicities are neutropenia (in 90% of patients), leukopenia (in 90% of patients), anemia (in 78% of patients), bleeding (in 25% of patients), thrombocytopenia (in 20% of patients), infections (in 14% of patients), and hypersensitivity reactions (in 41% of patients).
Although the hair loss associated with Taxol® treatment 1s not life threatening, it is typically viewed by both male and female patients as a sign of rapid progress of disease and produces anxiety and a loss of self-esteem in cancer
SUBSTITUTE SHEET (RULE 26)
' c } © WO 01/70220 PCT/US00/07619 patients. Clearly, the reduction or prevention of alopecia would increase the quality of life and outlook of a cancer patient during treatment. The reduction of other toxicities. such as neuropathy, would also provide an immediate benefit to cancer patients.
Strategies for reducing paclitaxel toxicity, have included pretreatment of patients with antihistamine and corticosteroids, and by prolonging the infusion time from six to twenty four hours. U.S. Patent No. 5,621,001 (Canetta et al.) discloses a prolonged infusion time in a method for reducing peripheral neuropathy symptoms while maintaining an anti-tumor effect in patients suffering from ovarian cancer and undergoing paclitaxel therapy. This method involves reducing the amount of paclitaxel administered in a treatment from 175 mg/m’ to about 135 mg/m? and increasing the administration time to about 24 hours. The administration of paclitaxel is repeated at least once, about 21 days after the preceding administration.
U.S. Patent No. 5,665,761 (Canetta et al.) discloses a pretreatment stage before administration of paclitaxel. The ‘761 patent provides for paclitaxel infusions over a duration of less than six hours, preferably about three hours, utilizing dosages of between about 135 mg/m’ and about 275 mg/m’, preferably between about 135 mg/m’ and about 175 mg/m’, after patients had been pretreated to alleviate or minimize hypersensitivity responses. For example, the patients were pre-medicated with steroids, antihistamines, and H,-antagonists sufficient to at least prevent an anaphylactoid shock capable of causing acute hypersensitivity reactions and patient death. U.S. Patent No. 5,670,537 (Canetta et al.) also discloses this method of administration for a patient suffering from a paclitaxel-sensitive tumor, such as an ovarian tumor.
U.S. Patent No. 5,641,803, discloses the administration of paclitaxel to a patient, wherein about 135-175 mg/m’ of paclitaxel is administered over a period of about three hours. Such a period purportedly was used to overcome, in part, some of the aforementioned problems associated with shorter infusion times, such as one hour, which had been employed with the conventional paclitaxel formulations containing polyethoxylated castor oil.
In yet another attempt to address the toxicity concerns of the conventional paclitaxel formulation, U.S. Patent No. 5,696,153 suggests the use of an administration regimen wherein lower amounts of paclitaxel of from 45 to 120 mg/m’ is administered over a period of 60 to 180 minutes, a plurality of times during a 21 day period. with each infusion being separated by an interval of between 4 to 5 days.
SUBSTITUTE SHEET (RULE 26)
w 1
However, even with prolonged infusion times and pretreatments with antihistamines and corticosteroids, patients suffer from toxicities, such as alopecia, neuropathy, and other toxicities, some of which are life threatening. Therefore, new drug delivery systems are needed that can enhance the efficacy and/or reduce 5S systemic toxicity.
U.S. Patent No. 5,648,090 (Rahman et al.) and U.S. Patent No. 5,424,073 (Rahman et al.) provide a liposomal encapsulated paclitaxel, or antineoplastic derivative, which is used to treat cancer in mammals. The '090 and "073 patents disclose a method of modulating multidrug resistance in cancer cells in a mammalian host by administering to the host a pharmaceutical composition of a therapeutically effective number of liposomes that contain cardiolipin and a taxane in a pharmaceutically acceptable excipient. Methods for using those compositions in humans in a manner that reduces toxicity, such as alopecia, neuropathy, nausea are not disclosed.
Currently, the only methods known for reducing the toxicity of paclitaxel : treatment in humans is to reduce the amount and/or rate of the drug administered to patients. The only approved protocol for administering paclitaxel is that for
Taxol® in the New Drug Application (“NDA”)owned by Bristol-Myers Squibb.
This protocol is limited to Taxol® dosages of no more than 175 mg/m’ and administration times of no less than three hours. In addition, all patients are premedicated with corticosteroids, diphenhydramine and H, antagonists. Even under these conditions, in addition to other adverse reactions, it is reported that approximately 60-70% of patients experience neuropathy and 87% experience alopecia. Consequently, there remains a need for 2 method of administering larger quantities of taxane in a shorter period of time which is accompanied by less frequent and less severe adverse reactions. Such methods would improve the efficacy of taxane therapy and alleviate the discomfort and complications that restrict current taxane administration methods. The present invention provides such a method.
The present invention provides a method for reducing adverse reactions such as neuropathy and alopecia, in human patients undergoing paclitaxel treatment. The method involves administering high concentrations of paclitaxel to patients over a period of about one hour or less. Concentrations of about 90, 135, 175, 250. and up to about 300 mg/m’ of paclitaxel are administered to patients within one hour. Surprisingly, the occurrence of adverse reactions like alopecia
SUBSTITUTE SHEET (RULE 26)
a t © WO 01/70220 PCT/US00/07619 and neuropathy, including peripheral neuropathy, are reduced as compared to the frequency and severity of adverse reactions reported for the administration of
Taxol® described previously. Paclitaxel is administered to patients in a liposomal formulation containing cardiolipin, cholesterol, a-tocopherol and the liposome- forming material, phosphatidylcholine. The formulation can be prepared as described below in Example 1. The present method also contemplates optional patient premedication as described in Example 3.
The present invention provides a method of administering relatively high concentrations of taxane to human patients over a short period of ime. For example, taxane can be administered to humans in less than an hour in an amount from about 75 to 300 mg/m’. Unique liposomal formulations of paclitaxel or its antineoplastic derivatives facilitate such treatments. The method does not require premedication, as with anti-hypersensitivity agents. As a result, the present invention provides an improved method for treating cancer with taxane.
These and other advantages of the present invention, as well as additional inventive features, will be apparent from the description of the invention provided herein.
The invention may best be understood with reference to the following detailed description of the preferred embodiments.
The present invention provides a method of administering a taxane to a patient, especially a human patient, in need of treatment with a taxane. In part, the present invention provides a delivery system for a taxane to a host which is characterized by the avoidance of taxane solubility problems; improved taxane stability; the avoidance of anaphylactic reactions, cardiotoxicity, alopecia, neuropathy; the ability to administer a taxane as a bolus or short infusion, rather than an extended infusion of free taxane; the increased therapeutic efficacy of taxane; and the modulation of multidrug resistance in cancer cells.
The taxane or antineoplastic derivative thereof, is delivered in a liposomal formulation. Any suitable taxane or derivative can be used in the present method.
Suitable taxanes when used in accordance with the disclosed methods provide the aforementioned benefits. Preferably, the taxane is paclitaxel. A suitable derivative of paclitaxel is taxasm. Other suitable taxanes are 7-epipaclitaxel, t- acetyl paclitaxel, 10-desacetyl-paclitaxel, 10-desacetyl-7-epipaclitaxel, 7-
SUBSTITUTE SHEET (RULE 26)
xylosylpaclitaxel. 10-desacetyl-7-glutarylpaclitaxel, 7-N,N- dimethylglycylpaclitaxel, 7-L-alanvipaclitaxel, taxotere, and mixtures thereof. .
The pharmaceutical composition may also include a suitable cardiolipin.
Suitable cardiolipin may be from either a natural or synthetic source. The taxane, 5s such as paclitaxel, is encapsulated in liposomes using the cardiolipin. In addition to cardiolipin, the taxane may be encapsulated in liposomes with phosphatidylcholine and cholesterol. Such lipid compositions provide over 90% encapsulation of the drug in liposomes.
The liposomal encapsulated taxane can be prepared by any suitable process.
For example, the taxane or a derivative thereof can be dissolved in a suitable solvent. Generally, suitable solvents are non-polar or slightly polar and can be evaporated without leaving toxic residue behind. Suitable solvents include such diverse solvents as ethanol. methanol, chloroform, butanol or acetone. Cardiolipin can also be dissolved in a suitable solvent as described for taxane and the taxane and the cardiolipin solutions can be mixed. The remaining lipophilic material can be dissolved in a suitable solvent, which may be the same as or different from the taxane containing solvent. The solvent will have low polarity such as chloroform, butanol or a non-polar solvent, such as n-hexane. The solvent mixture containing the taxane and cardiolipin can be mixed with the solution containing the remaining lipophilic components.
The solvent is removed, from the mixture by a suitable method such as by lyophilization to produce a dry lipid film that contains the drug. The mixture is stored in this form, optionally under an inert gas atmosphere, such as an N, atmosphere. The dry lipid film can be stored at low temperatures, such as —20° C for extended periods of time until liposomes are hydrated and prior to use.
Liposomes can be formed by adding any suitable solution to the lipid film.
Typically, suitable solutions are polar solutions, preferably, aqueous saline solutions. Once the solution is added, liposomes can be formed by mixing, for example, as by vortexing. Where smaller vesicles, such as unilamellar vesicles, are desirable the solution can be sonicated. In certain methods, suitable preparations can be mixtures of multilamellar vesicles and unilamellar vesicles.
The liposome is a closed structure composed of lipid bilayers surrounding an internal aqueous space. Generally, the liposomes may be neutral, negative or positively charged. Cationic liposomes can be formed from a solution containing phosphatidyl choline, cholesterol, and stearyl amine. Anionic liposomes can be formed, for example, from solutions containing phosphatidyl choline. cholesterol, and phosphatidyl serine or more preferably, cardiolipin. Other additives can also
SUBSTITUTE SHEET (RULE 26)
] + WO 01/70220 PCT/US00/07619 be included in the liposomes to modify the properties of the resulting preparations.
For example, preferred preparations also include a-tocopherol.
Storage conditions can vary. Preferably, mixtures of lipophilic components are stored as dry lipid films at about -20°C. Once hydrated, liposome suspensions of the pharmaceutical composition can be stored and are stable in buffered or unbuffered saline solutions for periods of hours to months, depending upon the temperature, paclitaxel content, and phospholipid constituents.
The liposomal drug delivery system which features a high drug to carrier ratio can alter drug pharmacokinetics, maintaining the plasma concentration of the drug at an increased level over a longer period of time. The biodegradability and the low inherent toxicity and immunogenicity of liposomal preparations reduces toxicity with respect to free-floating taxanes in the plasma.
The present liposomal formulations provide a drug-delivery system which allows infusion of high concentrations of taxane in a relatively stable form and which provides sustained therapeutic benefits at target sites, while maintaining low concentrations of insoluble frec taxane and minimal adverse toxic effects than were previously known. For cxample, infusion of encapsulated paclitaxel provides higher peak plasma concentrations, longer presence of the drug in the body, and higher AUC (“area under the curve” measurement of plasma concentration over time) than the conventional paclitaxel.
The present pharmaceutical composition can be administered in amounts of at least 50 to 300 mg of active compound/m’ of patient surface area, within a period of about one hour or 45 minutes such that adverse reactions are reduced in patients. Longer administration times may be used but this is not preferred. For example, in a 70 kg human, about 0.5 to 5.0 mg active compound per kg of body weight can be safely administered in about 45 minutes. Preferably, about 1.0-3.0 mg of active compound per kg of body weight is administered. Alternatively, amounts of 75, 135, 175, 250, and 300 mg/m’ can be administered.
Liposomal encapsulated taxane has a substantial beneficial effect in overcoming multidrug resistance in cancer cells which are subjected to chemotherapy. By using the liposomal composition of the present invention, it is possible to reduce the tendency of cancer cells subjected to chemotherapy to develop resistance to the chemotherapeutic agents used for chemotherapy such as anthracycline glycosides. This method includes administering to a host a pharmaceutical composition of a liposomal encapsulated taxane of the present invention in accordance with the administration protocol.
SUBSTITUTE SHEET (RULE 26)
EE
Taxanes and the anti-neoplastic derivatives thereof may be used to treat any disease that is susceptible to treatment. Such compounds are thought to function . by promoting the assembly of microtubules or prohibiting the tubulin disassembly process. These compounds are particularly advantageous in the treatment of taxane sensitive diseases such as mammalian lymphoma, ovarian. breast, lung and colon cancer, and particularly those conditions in humans.
The present liposome compositions can be administered intravenously, intraperitoneally, to an isolated portion of a mammalian body, particularly a human body, such as an arm or leg, or in the case of a human, a hand, or can be injected directly into a tumor.
The following examples further illustrate the present invention but, of course, should not be construed as in any way limiting its scope.
EXAMPLE 1
Paclitaxel can be encapsulated in liposomes of cardiolipin, phosphatidyicholine, cholesterol and a-tocopherol. The composition described in this example, provides for over 90% encapsulation of the drug in liposomes. The paclitaxel in liposomal formulation is stable for days at room temperature and at - 20°C for at least 5S months. No degradation or precipitation of paclitaxel is observed at any storage temperature and the preparation appears to be ideally suited for systemic administration in accordance with the present invention.
The proportion of lipids per mg of paclitaxel is: 1.8 mg cardiolipin 9.0 mg phophatidylcholine 3.0 mg cholesterol 0.1 mg o-tocopherol
The liposome encapsulated paclitaxel can be manufactured using the following procedure. 8.89 kilograms of t-butyl alcohol are added to a 12.0 liter flask and heated to 40-45° C. The following additions are made sequentially with mixing until dissolution and heating at 40-45° C: 3.412 grams of D-q-tocopherol acid succinate, 205 grams of egg phosphatidylcholine, 22.78 grams of paclitaxel, 41.00 grams of tetramyristoyl cardiolipin, 68.33 grams of cholesterol.
The resulting solution is filtered through a 0.22 micron filter and filled into sterile vials, each containing about 10.1 grams of filtrate. The vials are stoppered and subjected to lyophilization. They can be stored at —20° C until use.
SUBSTITUTE SHEET (RULE 26)
. woote PCT/US00/07619
Liposomes are prepared from the dry lipid film, as needed. with 25 mi of normal saline solution. The mixture is allowed to hydrate at room temperature for about one hour, after which time the vials are vortexed for about one minute and sonicated for about 10 minutes in a bath type sonicator at maximum frequency. An appropriate amount of the contents of the vial can be transferred to an infusion bag and infused into a patient in accordance with the present invention.
EXAMPLE 2
The following study demonstrates that a large quantity of taxane can be rapidly administered to humans without inducing a substantial toxic reaction.
Both hematological toxicity and nonhematological toxicity were evaluated. In addition, the study was used to determine in human patients the dose-limiting toxicity, the maximum tolerated dose and the untolerated dose for the liposomal formulation described in Example 1.
Vials containing liposomal paclitaxel were prepared as in Example 1. The preparations were 1 mg/ml paclitaxel in liposomes. The contents of the vials were transferred to infusion bags at the appropriate dosages and administered to patients over about a 45 minute period.
Patients selected for the study had a measurable or evaluable metastatic or locally recurrent malignancy and had no significant hope of cure or palliation by other conventional therapies. In addition, they had no evidence of spinal cord compression or carcinomatous meningitis. Patients had not undergone chemotherapy or radiotherapy within the four weeks prior to treatment. Those patients that had undergone prior chemotherapy or radiotherapy exhibited complete hematologic recovery prior to treatment in this study. All patients had an
ECOG (Eastern Cooperative Oncology Group) performance status of 0 or 1 and had a life expectancy of at least 3 months. Patients in the study were all over the age of 18, were free of infection and had recovered from the effects of any major surgery which must have occurred more than three weeks prior to entering the study. Within the immediate two weeks prior to the instant tests all patients had a white blood cell count of over 3000/mm’, a platelet count of over 100,000/mm’, serum creatinine of less than 1.8 mg/dl or creatinine clearance of more than 60/cc/min and serum bilirubin of less than 1.5 mg/dL
Treatments were administered intravenously over about a 45 minute period.
At least three patients were treated at each dosage level. Dosages were about 90 mg/m’, 135 mg/m’, 175 mg/m’, 250 mg/m’, and 300 mg/m’ allowing for normal laboratory and therapeutic dose variation. The formulation was given as a single
SUBSTITUTE SHEET (RULE 26)
y agent without pretreatment with steroids. antihistamines or other therapeutic agents such as anaphylaxis inhibitors. Where the treating physician considered it appropriate. treatments were repeated every 21 days. Each patient was subjected to a single treatment regimen.
Hematologic and nonhematological toxicities were evaluated in patients by the evaluation of blood specimens in accordance with methods well known in the medical arts. Drug efficacy was also evaluated. The results of this study are shown in Table 1 below.
Common toxicity grades established by the National Cancer Institute were employed to determine drug toxicity. Dose-limiting toxicity is defined as any grade 3 or higher non-hematologic toxicity for 7 or more days occurring during cycle 1 of chemotherapy. An untolerable dose is defined as the dose level at which at least 1/3 to 2/3 of the patients have dose-limiting toxicity. The maximum tolerated dose level is defined as the dose level at which 0/6 or 1/6 patients experience dose-limiting toxicity and at least 2/3 or 4/6 patients treated at the next higher dose level experience dose-limiting toxicity.
This study demonstrated that a large quantity of taxane could be administered to a human without inducing a substantial hematological or nonhematological toxic reaction. Nonhematological toxicity was generally minor but became more pronounced at the highest dosage level. Similarly, hematological toxicity was mild but became more pronounced at the highest dosage. At least 300 mg/m’ of taxane could be administered to a human patient in a 45 minute period without inducing very substantial hematological toxicity. The dose limiting toxicity was about 300 mg/m® when drug was administered in a 45 minute period.
The untolerable and maximum tolerable doses were not yet determinable from this study but were at least 250 mg/m’. With one exception, the cancer had not progressed or was improved in each of the patients studied.
SUBSTITUTE SHEET (RULE 26)
« A 1
A
: Q ~L A . 2 A . eo . . < | 0 2 als ally | A a > a. al el D a) ae a, [= ! = eT) I
E
= ©)
L wy go!
Pe 0 =)
O a 0 i] > ex of © ol 8 Q ° = ofl © of bo r=) a 5 cS | O <3
S| 8 sl 8 S g oa nn wn 7] = 3 oi 2 £ Ty =D 5 S| [5 0 eo «© on > = p= <n = 2 & oo a] 2 - a = Q > R2] Q ES Sh — 1° = 3 8 20 hn w |= go 5 © 2 Z| of 213 ] z <5 SRR a m By 5] © oh < = © U <|& 2 & =£ zl =f 2) & = = ° Ll = .2] wv La 21» Q on 5
S So |S TEE 2g | EE 8 Le 4 oS — I'S) g] +— <Q <n [] xl] = 0 cs > S S a ou 4 | | on] oo A [= 2) Sl 3 ol ol oe] ad ~~] 21 FY FE = 2 “ 5 3 [0 £ <| Bl © =2° =| OC b= _— a py c |x |S g<Si=e2E = 2 2 EES a oO wn | T= Q = o— _] = Oo] = 3 z |2 | 2258555358535 23] 4 a ‘ i XX y 6] = a
[8] QL
SE REZ SIRE |Z == 55 X
Ecol 5 Z| = = =| = = = =| = ol © o
TX zl Z| = SS 22 | == =] IID TY I WE = oC §356 i NE I LoL Qyet -ct : : hal - u & wy wn wn ol © ol of of ol © oH v Elgg gl a ~~ | n al A SSD 6g 2 a — —_— = NN Nl ON en] on) en Hon ; FESR q] af | | 5 : : : i : ~ m2 i» | | LXE:
HE | E = { vA J ; i Q >a £9 + i i Dm £9] a] =| vo] ov] © El el ef — lL A&E CEE
LO | ! “ert - | | fhe cue + [VI ol} : a8
S | | “80 - elt; 5=< 3 00> 2 E —| | en] =| nf of | 0] —_ ~~ nf | no Ls == ol of of oO oo] S| of oO © — —| = =] =| = el SOO oO oO Do ele > of of of oo) © Cw =
SUBSTITUTE SHEET (RULE 26)
Lo?
EXAMPLE 3
The data reported in Example 3 demonstrates that the methods of . the present invention can be used to treat patients with higher concentrations of paclitaxel and with reduced adverse reactions, especially including reduced neuropathy and alopecia as compared to the incidence reported for Taxol® in the Physicians Desk Reference, 54th Edition and
U.S. Patent No. 5,621,001 (Caretta et al.). The present example incorporates data from Example 2 above along with data from the study of 10 additional patients and observations after further treatments of patients 2, 5, 6, 13, and 15 over that reported in Example 2. Adverse drug reactions were determined using standard medical procedures. All observations are reported in Tables 2- 4 below which provide cumulative results for all 26 patients. Patients were evaluated for the adverse reactions listed below and neuropathy, which has not yet been observed in any patient treated in these studies. Patients 1-19 were not premedicated while patients 20-26 were premedicated with diphenhydramine 25/50 mg and hydrocortisone (100 mg) using standard procedures.
TABLE 2
Number Cycles mg/m’ oot | ef | wscc' | 2 | 90 Progression 002 68/M NSCLC | 20+ | 90 |Stable 005 | eom | Nscic | 6 | 90 Progression os | 7uF | Nscc | 6 | 135 [subtle 006 | 64F | NscLC | 17+ | 135 |Minor Response 09 | evr | nso | 1 | 17s [None 4 | 250 !stble 016 i J2/F + NSCLC 3 300
SUBSTITUTE SHEET (RULE 26)
© WO 01/70220 PCT/US00/07619 (Table 2-continued) 019 020 | som 02l__| 46 |masopharyneeal| 3 | 175 Isuble 22 24 | seM | wiknown | 2+ | ws bs | ssp | wsac | oa | ows ve ows [0 + Patients continuing on study , NSCLC is non-small cell lung cancer
SCLC is small cell lung cancer ” Table 2 provides an indication of the efficacy of the present method against various types of cancer. A partial response was observed in two patients, one having breast cancer and another having non-small cell lung cancer. The breast cancer patient received a 175 mg/m’ dose and the lung cancer patient received a dose of 300 mg/m’. A minor response was observed in another non-small cell lung cancer patient at 135 mg/m’ and a breast cancer patient who received 300 mg/m’ of paclitaxel. In six additional patients the disease was stabilized by the present methods.
Stabilization was observed in one patient suffering from nasopharyngeal cancer after treatment with a dose of 175 mg/m” paclitaxel. Five patients suffering from non-small cell lung cancer were stabilized by the present treatment at doses of 90 (1 patient of 3), 135 (1 patient of 3), 175 (2 patients of 8 evaluated), and 250 mg/m’ (2 patients of 6).
One aspect of the present invention is the reduction in hematologic ~~ toxicity associated with the present paclitaxel treatment. Patient blood samples were analyzed as described in Example 2 for white blood cell count (WBC), absolute neutrophil count (ANC), platelet counts (Plt), and hemoglobin concentration and World Health Organization grades were assigned to patients. Table 3 provides a summary of hematologic toxicity.
As shown in Table 3, dose dependent neutropenia was the most significant adverse reaction observed in the present study at dosages of 250 and 300 mg/m’. At a dosage of 250 mg/m’ one patient experienced grade 4 neutropenia leading to sepsis and death. Significant instances of
SUBSTITUTE SHEET (RULE 26)
leukopenia were also observed at the higher dosages. The incidence of thrombocytopenia and anemia was lower and less severe. -
TABLE 3 patiens | Gra Grade 2 | Gn mg/m’ Patients Grade 3/4 | Grade 3/4 | Grade 2/3 | Grade 2/3 (90 13 dom foo [0/0 JOO mr jo3 f30 [2/0 0 [10] 300 3 0/3 1/2 0/2 1/1
The incidence and spectrum of nonhemotologic toxicity is summarized in Table 4. Surprisingly, Table 4 shows that no alopecia was observed in patients treated with either 90, 135, and 175 mg/m’ of paclitaxel. At a dosage of 250 mg/m’ paclitaxel only one case of grade 2 alopecia was observed out of a total of 6 patients. Similarly, the incidence and severity of alopecia at the highest dose of 300 mg/m’ was remarkably low. Out of three patients at this dosage level, only one exhibited grade 2 alopecia and one patient exhibited grade 1 alopecia. Overall the incidence and severity of alopecia is profoundly reduced from the levels associated with Taxol® treatment by known and approved methods.
TABLE 4 mg/m’ Patients 90&135 |6 [1 JI [diarhea (175 [il [IT |3 = [neutropenicfever pir fr 12 | mucositis 11m [3 [1 [diarrhea & fatigue 250 |6 [1:1 [4 |bronchospasm:eutropenic fever 16 IT [3 mucositis 16 — TLrt — 2 |fatigue:N/V:ialopecia 2 3/4 | mucositis 13 nad i 3 diarrhea:N/V: neutropenic fever 3 mr 72 Talopeciafatigue 3 IT JU Jalpeein
Quite surprisingly, no neurological toxicity was observed when paclitaxel was administered by the present methods, at any dose level.
More specifically, none of the patients treated in this study appeared to exhibit peripheral neuropathy. arthralgia. or myalgia. This observation is
SUBSTITUTE SHEET (RULE 26)
voy 4 14 Cl quite remarkable given the short administration times of approxindately 45 ) minutes and the high concentrations of up to 300 mg/m’ paclitaxel. The incidence of neuropathy observed in the present study is a particularly surprising and profound reduction from the 60 to 70% incidence reported for prior Taxol® treatment methods.
At a dosage of 250 mg/m’ one patient experienced grade 4 bronchospasm. At 300 mg/m’ one patient experienced a grade 3/4 mucositis which led to sepsis and death after each of three cycles of therapy in which the doses were reduced from 300 to 250 to 175 mg/m’. Another patient experienced grade 3 mucositis at this dose level.
In the group of patients that were not premedicated 6 exhibited some form of infusion toxicity. Of this group 3 patients exhibited moderate flushing and severe back pain, 1 patient exhibited moderate flushing and back pain, 1 patient exhibited mild flushing, and 1 patient exhibited moderate rigors.
All of the references cited herein, including patents, patent applications, and publications, are hereby incorporated in their entireties by reference.
While this invention has been described with an emphasis upon preferred embodiments, it will be obvious to those of ordinary skill in the art that variations of the preferred embodiments may be used and that it is intended that the invention may be practiced otherwise than as specifically described herein. Accordingly, this invention includes all modifications encompassed within the spirit and scope of the invention as defined by the following claims.
SUBSTITUTE SHEET (RULE 26)
Claims (19)
1. Use of paclitaxel in the manufacture of a medicament for reducing neuropathy in a human patient undergoing paclitaxel treatment, by administering to said patient from about 135 to about 300 mg/m? of said medicament in a liposomal formulation over a period of about one hour.
2. Use of paclitaxel in the manufacture of a medicament for reducing peripheral neuropathy in a human patient undergoing paclitaxel treatment, by administering to said patient from about 135 to about 300 mg/m? of said medicament in a liposomal formulation over a period of about one hour.
3. Use of paclitaxel in the manufacture of a medicament for reducing alopecia in a human patient undergoing paclitaxel treatment, by administering to said patient from about 135 to about 250 mg/m? of said medicament in a liposomal formulation over a period of about one hour.
4. Use of paclitaxel in the manufacture of a medicament for reducing alopecia and neuropathy in a human patient undergoing paclitaxel treatment, by administering to said patient from about 135 to about 250 mg/m? of said medicament in a liposomal formulation over a period of about one hour.
5. Use of paclitaxel in the manufacture of a medicament for reducing alopecia and neuropathy in a human patient undergoing paclitaxel treatment, by administering to said patient from about 135 to about 250 mg/m? of said medicament in a liposomal formulation comprising a liposome-forming material, cardiolipin, and a pharmaceutically acceptable excipient.
6. Use according to any one of claims 1-5 wherein said patients are premedicated before administering said paclitaxel. AMENDED SHEET
FE o : | PCT/US00/07619
7. Use according to any one of claims 1 or 2 further comprising administering to said patient about 300 mg/m? of paclitaxel in a liposomal formulation.
8. Use according to any one of claims 1-6 further comprising administering to said patient about 250 mg/m? of paclitaxel in a liposomal formulation.
9. Use according to any one of claims 1-6 further comprising administering to said patient about 175 mg/m? of paclitaxel in a liposomal formulation.
10. Use according to any one of claims 1-6 further comprising administering to said patient about 135 mg/m? of paclitaxel in a liposomal formulation.
11. A substance or composition for use in a method for reducing neuropathy in a human patient undergoing paclitaxel treatment, said substance or composition comprising paclitaxel, and said method comprising administering to said patient from about 135 to about 300 mg/m? of said substance or composition in a liposomal formulation over a period of about one hour.
12. A substance or composition for use in a method for reducing peripheral neuropathy in a human patient undergoing paclitaxel treatment, said substance or composition comprising paclitaxel, and said method comprising administering to said patient from about 135 to about 300 mg/m? of said substance or composition in a liposomal formulation over a period of about one hour.
13. A substance or composition for use in a method for reducing alopecia in a human patient undergoing paclitaxel treatment, said substance or composition comprising paclitaxel, and said method comprising administering to said patient from about 135 to about 250 mg/m? of said substance or composition in a liposomal formulation over a period of about one hour. AMENDED SHEET
, . : PCT/US00/07619
14. A substance or composition for use in a method for reducing alopecia and neuropathy in a human patient undergoing paclitaxel treatment, said substance or composition comprising paclitaxel, and said method comprising administering to said patient from about 135 to about 250 mg/m? of said substance or composition in a liposomal formulation over a period of about one hour.
15. A substance or composition for use in a method for reducing alopecia and neuropathy in a human patient undergoing paclitaxel treatment, said substance or composition comprising paclitaxel, and said method comprising administering to said patient from about 135 to about 250 mg/m? of said substance or composition in a liposomal formulation comprising a liposome-forming material, cardiolipin, and a pharmaceutically acceptable excipient.
16. A substance or composition for use in a method of treatment according to any one of claims 11-15 wherein said patients are premedicated before administering said paclitaxel.
17. A substance or composition for use in a method of treatment according to any one of claims 11 or 12 further comprising administering to said patient about 300 mg/m? of paclitaxel in a liposomal formulation.
18. A substance or composition for use in a method of treatment according to any one of claims 11-16 further comprising administering to said patient about 250 mg/m? of paclitaxel in a liposomal formulation. _
19. A substance or composition for use in a method of treatment according to any of claims 11-16 further comprising administering to said patient about 175 mg/m? of paclitaxel in a liposomal formulation. AMENDED SHEET
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
ZA200100454A ZA200100454B (en) | 2001-01-16 | 2001-01-16 | A method of administering liposomal encapsulated taxane. |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
ZA200100454A ZA200100454B (en) | 2001-01-16 | 2001-01-16 | A method of administering liposomal encapsulated taxane. |
Publications (1)
Publication Number | Publication Date |
---|---|
ZA200100454B true ZA200100454B (en) | 2002-12-24 |
Family
ID=27735282
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ZA200100454A ZA200100454B (en) | 2001-01-16 | 2001-01-16 | A method of administering liposomal encapsulated taxane. |
Country Status (1)
Country | Link |
---|---|
ZA (1) | ZA200100454B (en) |
-
2001
- 2001-01-16 ZA ZA200100454A patent/ZA200100454B/en unknown
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AU730599B2 (en) | A method of administering liposomal encapsulated taxane | |
US6461637B1 (en) | Method of administering liposomal encapsulated taxane | |
Straubinger | Biopharmaceutics of paclitaxel (Taxol): formulation, activity, and pharmacokinetics | |
Cabanes et al. | Comparative in vivo studies with paclitaxel and liposome-encapsulated paclitaxel. | |
US20030219476A1 (en) | Liposomal formulation of mitoxantrone | |
US20050249795A1 (en) | Gemcitabine compositions for better drug delivery | |
KR20200083657A (en) | Compositions and methods of delivery of pharmacological agents | |
WO1994026253A1 (en) | Liposome having a multicomponent bilayer which contains a bioactive agent as an integral component of the bilayer | |
CA2676986A1 (en) | Pharmaceutical composition comprising a campothecin derivative | |
DE60025494T2 (en) | EPOTHILONE COMPOSITIONS | |
US8859001B2 (en) | Fenoldopam formulations and pro-drug derivatives | |
WO2003105765A2 (en) | Phospholipid micelles in liposomes as solubilizers for water-insoluble compounds | |
US20050019386A1 (en) | Orally administered pharmaceutical preparation comprising liposomically encapsulated paclitaxel | |
WO2001070220A1 (en) | A method of administering liposomal encapsulated taxane | |
US20040228911A1 (en) | Vinorelbine compositions and methods of use | |
US7314637B1 (en) | Method of administering liposomal encapsulated taxane | |
ZA200100454B (en) | A method of administering liposomal encapsulated taxane. | |
EP1596825A2 (en) | Stable sterile filterable liposomal encapsulated taxane and other antineoplastic drugs | |
EP1313449B1 (en) | Amphotericin b structured emulsion | |
CN104971062A (en) | Irinotecan and chloroquine pharmaceutical composition and common carrier liposome and preparation thereof | |
NZ262160A (en) | Anticancer drug with cytotoxic substance formulated with a low density 1ipoprotein | |
MXPA00002170A (en) | A method of administering liposomal encapsulated taxane | |
RU2361615C2 (en) | Compositions and ways of pharmacological agents delivery | |
CZ20001046A3 (en) | Pharmaceutical composition containing taxane |